Introduction and Objective: Short-term use of a single stand-alone 14-day continuous glucose monitoring (CGM) improves glycemic awareness and self-management in non-insulin-treated (NIT) patients with type 2 diabetes (PwT2D). This study examined whether supplementing short-term CGM use of 9-14 days with access to a digital learning platform or a blended in-person course and webinar enhances self-reported […]
Read MoreCategory: Diabetes
1334-OR: Hepatocyte-Derived THBS2 Encodes Metabolic Stress to Orchestrate Immune-Stromal Remodeling
Introduction and Objective: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by chronic immune activation and stromal remodeling; however, the paracrine mechanisms linking parenchymal metabolic stress to immune-stromal responses remain poorly understood. This study aimed to identify key paracrine signals driving inflammatory and fibrogenic remodeling in MASH and to define their downstream mechanisms.Methods: Integrative transcriptomic and secretome […]
Read More1338-OR: Time and Educational Needs Required for Older Adults on Continuous Glucose Monitoring: A Mixed-Methods Study
Introduction and Objective: Older adults benefit from continuous glucose monitoring (CGM) use, but CGM initiation and sustained use often require intensive educator support, and time requirements are poorly characterized. We quantified educator time and support needs during the REST study.Methods: REST is a prospective 12-month study conducted in older adults (≥65 years) with insulin-treated diabetes, […]
Read More1300-OR: Performance of the iCan CGM System in a Pediatric Sample from a U.S. Multicenter Study
Introduction and Objective: The iCan CGM system is equipped with 3rd generation sensor technology and based on a different enzyme (GDH-FAD) than other FDA approved CGM systems in US. This 15d factory calibrated sensor is available in many regulated markets worldwide and was evaluated in a multi-center study for iCGM compliance in a pediatric sample […]
Read More1307-OR: Site-Specific Cancer Risk across Type 2 Diabetes Subtypes and Adults without Diabetes in a Real-World Cohort of 1.2 Million Adults
Introduction and Objective: Type 2 diabetes (T2D) is associated with elevated cancer risk, yet whether heterogeneity in T2D identifies individuals at particularly high or low risk relative to individuals without diabetes remains unclear. We evaluated site-specific cancer risk across T2D subtypes compared with adults without diabetes.Methods: We analyzed retrospective electronic health records from Epic Cosmos […]
Read More1317-OR: Optimized Protocol for Rapid Functional β-Cell Generation from Human Pluripotent Stem Cells
Introduction and Objective: Despite recent improvements in generating functional human insulin-producing β cells, stem cell-derived beta-like cells (sBC) still develop and function less efficiently than bona fide β cells from cadaveric islets. Therefore, we sought to identify key factors affecting efficient sBC generation during differentiation, with a focus on reducing time for sBC generation while […]
Read More1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year
Introduction and Objective: Use of dual glucagon-like-peptide-1/glucose-dependent insulinotropic polypeptide receptor-agonists is increasing in overweight/obese (OW/OB) individuals with T1D. Their effects on DR in individuals with T1D are unknown.Methods: Retrospective chart review of OW/OB individuals with T1D at the Barbara Davis Center for Diabetes. Individuals who used tirzepatide for 12 ± 2 months (cases) were matched […]
Read More1289-OR: Effect of Different Treatment Durations of Sodium–Glucose Cotransporter 2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Target Trial Emulation Study
Introduction and Objective: Despite cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longer treatment durations offer greater cardiovascular benefits.Methods: We used nationwide healthcare data of South Korea (2012-2023) to emulate a target trial comparing following treatment strategies: treated with SGLT2i for <1 year, 1-2 […]
Read More1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice
Introduction and Objective: T2DM is often driven by obesity, which leads to impaired glucose homeostasis and β-cell dysfunction. While oral small-molecule GLP-1RAs, such as orforglipron, promote weight reduction, dose-dependent gastrointestinal adverse effects can limit adherence. Dorzagliatin, a first-in-class glucokinase activator, enhances glucose sensing and early-phase insulin secretion. We evaluated whether combining these two oral agents […]
Read More1285-OR: HYPO-VR: Virtual Reality Training Program to Improve Peer Recognition and Response to Hypoglycemia on College Campuses
Introduction and Objective: Transitioning to college increases the risk for hypoglycemia due to irregular schedules, alcohol use, and unpredictable access to food or glucose, highlighting the need for campus-based training to improve hypoglycemia-related safety. This study evaluated the effectiveness of HYPO-VR for on-campus hypoglycemia education.Methods: We conducted a two-arm pilot educational trial with undergraduate students. […]
Read More